For a reliable incidence of a disease, all the cases that occurred in the area during the period of interest should be diagnosed, registered and classified correctly. It is very important to know in comparisons which data sources a particular cancer registry is utilizing and for how long it is waited until a publication of incidence is released. Examples from Finland show that deficits of up to 5-25% are possible in leukaemia and multiple myeloma. The populations to be compared may also have large differences in the age distribution. As the risk of all cancer, also for leukaemia and lymphomas, increases strongly by age, it is crucial that care is taken about the age adjustment before showing the incidence rates for comparisons. The age adjustment can be done using different methods and standards. In practice, the choice of methods for comparative purposes is often not crucial. It is also essential to evaluate the age-specific rates when making comparisons between populations. For cancer prevalence it would be important to know which patients can be considered cured. A population-based cancer registry does not, as a rule, have this information. However, if a cancer registry follows up the patients, survival rates of the patients may, after a number of follow-up years, start to resemble those in a comparable general population group. This is an indication that the living patients are cured and should be deducted from cancer prevalence. Advances would also be needed in statistical methods and improvement in the quality and coverage of cancer registration.
Introduction
The occurrence of a disease, eg cancer, is measured by the incidence, prevalence and mortality. 1 The incidence gives the number of new cases divided by the number of persons and years (person-years) at risk during a specific time period, eg 1 or 5 years (eg 1997 or 1991-1995) . The prevalence gives the number of persons with existing disease divided by the total number of persons in the population at a certain date, eg 31 December 1997. Mortality expresses the number of deaths due to the disease divided by the number of person-years at risk during a specific time period.
Incidence is often the measure preferred as it gives the risk of contracting the disease in the population. Prevalence gives more weight to long-lasting disease cases and mortality discards the non-fatal cases entirely. The incidence is measured by population-based cancer registries. The last volume of Cancer Incidence in Five Continents 2 lists 183 populations for which there exists a population-based cancer registry. 
Cancer registries
For a reliable incidence of cancer, all the cases that occurred in the area or population during the period of interest should be diagnosed, registered and classified correctly. It is very important to know in comparisons which data sources a particular cancer registry utilizes. Moreover, public reporting of the numbers and rates should be delayed for a specified period in order to ensure that practically all cases diagnosed during a given time interval have been reported to the population-based cancer registry. 3 For example, the Finnish Cancer Registry is almost complete as it receives, on average, five notifications per case. Notification is enforced by law and the notifications come from physicians, hospitals, pathological, cytological and haematological laboratories as well as from the Central Statistical Office whenever cancer is mentioned. 4 Most cancer registries in Europe rely on voluntary reporting, and for example in England and Wales, quite heterogeneous sources of notification are used, depending on the region. 5 This creates heterogeneity in data quality both between countries and within a country.
The Finnish Cancer Registry 6 does not routinely make use of the countrywide Hospital Discharge Register as a source of notification but rather relies on direct reporting from the hospitals containing more detailed information on the tumour characteristics than a record in the Hospital Discharge Register. 4 From 1985 to 1988, haematological laboratories were not obliged to notify the Cancer Registry, and that was reflected in deficits of the order of 10-25% in different cell types of leukaemia and multiple myeloma ( Table 1 ). The comparable figures for lymphomas and solid tumours were of the order of 1-2%.
This analysis led to the inclusion of the haematological laboratories among the bodies reporting to the Cancer Registry. The Hospital Discharge Register, on the other hand, was not included as a source for cancer registration due to unreliability of the diagnoses. In about two-thirds of the cases that were supposedly missing from the Cancer Registry the cancer code proved after more detailed checks at hospitals to be erroneous in the Hospital Discharge Register. 4 It is important to know which data sources a particular registry utilizes. For example, with a view of the example above, a Finnish cancer registry without haematological laboratories as a data source would run a risk of having an incomplete ascertainment. On the other hand, basing the registration on the hospital discharge records would bring into the cancer registry a fair number of false positive cases. The Hospital Discharge Register's main goals are administrative purposes, and a reliable true diagnosis is less important than the diagnosis for which the patient was treated.
The timeliness of the incidence publication may also have been behind the case deficits.
3 Quite a few cases of multiple myeloma and leukaemia were missed in the printed publication for 1993 compared to the registry's data base for the publication of 2 years later ( Table 2 ).
There are some prerequisites for a successful cancer registration: individuals should be uniquely identifiable both with respect to identity and to whether a particular individual lives in the area of registration. A fairly stable population subject to basic health services provides the easiest but not the only possible basis when building up the cancer registration system. The denominator numbers on persons in the population should be available, too. Should not a population register be available, census data could provide the denominators needed. A system of follow-up of the patients either through patient contact or linking with vital status registers would help in determining the survival of the patients. A trained personnel and adequate funding should exist. A close collaborative relationship between scientists utilizing the data, (eg oncologists, pathologists, epidemiologists and statisticians) and the cancer registry results in the quality of the basic register being particularly high. In Finland this has been solved by having the cancer registry employ the scientists and thus making the cancer registry into a true research institute.
Age adjustment
Particularly in international comparisons, the populations to be compared may have large differences in the age distribution. The capital Quito in Ecuador has a typical population of a developing country, with an abundance of young persons in the population (Figure 1 ). The population of the city of Trieste in Italy shows the contrary: there is a deficit of young people and children (Figure 2 ). The Finnish population shows an intermediate pattern (Figure 3 ). As the risk of all cancers, also for lymphomas, multiple myeloma and leukaemia, increases strongly by age (Figure 4) , it is crucial that care is taken about the age adjustment before showing the incidence rates for comparisons. If the age adjustment is not done, a young population as in Quito, Ecuador, has a crude incidence of a disease reflecting the low incidence in the young age groups (Table 3 ). An old population as in Trieste, Italy, on the other hand, has a crude incidence corresponding to the high incidence in the old age groups.
An age (or age group)-specific incidence rate gives the incidence rate of the disease in a specific age group. With cancer, the usual width of this age group is 5 years. The age-adjusted rate, on the other hand, has been calculated for a wider range of age (all age groups or all age groups under 75 years as in Table 3 ). The idea is to produce a rate to be used in comparisons between populations in such a way that the differences in age structure between populations have been corrected for (adjusted for). There are different methods for age adjustment. 7 With all of these methods, the age-adjusted incidence rates are incidence rates that have been made mutually comparable with respect to age.
The different methods of direct age adjustment use different standards. In any case, the adjusted rates themselves only refer to a hypothetical situation where all the populations to be compared have an identical (often hypothetical) age distribution. The 'world standard population' is such a population, giving a hypothetical age distribution of the world's population a few decades ago. If it is assumed that instead of their real population age distributions the three areas to be compared had this world standard population's age structure, the incidence rates were very much closer to each other (Table  3) . Trieste still has a higher incidence of non-Hodgkin's lymphoma in males than Finland or Quito, but this comparison has now been corrected for (differences in) age (distribution).
In practice, the choice of the 'standard population' for comparative purposes is not crucial, even though the interpretation of the adjusted figure varies based on the method. For example, another method of age adjustment is to investigate only ages below 75 years and to assume that in each area all 5 year age groups under 75 years are of the same size, corresponding to a rectangular age structure for each area instead of the real age structures in Figures 1-3 . This age adjustment gives a newborn's risk of contracting the disease before the age of 75 given that the age-specific risks prevailed throughout the person's life. These risks are around 1% for non-Hodgkin's lymphoma in males in the three areas to be compared (Table 3) . That the ratios between these ageadjusted, the so-called cumulative, rates are approximately the same as the ratios between the age-adjusted rates using the world standard population illustrates the fact that the comparative inference will remain the same whichever standard is used.
A comparative analysis should never be restricted to the age-adjusted rates only. Age adjustment may hide important age-specific information, and an investigation of the agespecific rates is always recommended.
Prevalence
For the determination of prevalence it is important to know which patients can be considered cured, particularly nowadays when cure is becoming increasingly more common. A population-based cancer registry does not, as a rule, have this information. However, if a cancer registry follows-up the
S39

Figure 1
Age structure of population in Quito, Ecuador, from 1985 to 1987.
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Figure 2
Age structure of population in Trieste, Italy, from 1984 to 1987. 7 patients, survival rates of the patients may, after a number of follow-up years, start to resemble those in a comparable general population group. This is an indication that the living patients are cured and should be deducted from the prevalent cases. The point of cure can be seen by investigating the annual relative survival rates of the patients. When these rates are under 100% the patients have excess mortality compared to the general population group. When the rates are approximately 100% the patients can be considered cured. In Finland, the point of cure is reached after 5 years of follow-up for extra-nodal non-Hodgkin's lymphomas ( Figure 5 ) whereas no such point is reached during a 10 year follow-up for the nodal lymphomas ( Figure 6 ). The number of prevalent cases and thereby the prevalence varies strongly depending on for how many years after diagnosis the patients are considered not to be cured (cf. the cutoff point in Table 4 ).
The prevalence rates can be derived from the numbers of prevalent cases in Table 4 by dividing them with the appropriate total number of persons in the population in 1990. Exactly as the incidence rates, the prevalence rates need to be ageadjusted, should comparisons between different populations be in focus.
These analyses may become a routine but advances are 
Figure 4
Incidence of non-Hodgkin's lymphoma (NHL), Hodgkin's disease, multiple myeloma and leukaemia in males in Finland from 1990 to 1994, by age.
Table 3
Crude, age-adjusted and cumulative incidence rates, and rate ratios in non-Hodgkin's lymphoma in males in three different geographic areas 7 
Crude
World Cum −75 (/100 000) (/100 000) (%) 
Figure 5
Annual relative survival rates of extra-nodal non-Hodgkin's lymphomas in Finland from 1985 to 1994, by sex (males, squares; females, circles).
9
Figure 6
Annual relative survival rates of nodal non-Hodgkin's lymphomas in Finland from 1985 to 1994, by sex (males, squares; females, circles). 
